This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Silverstein, M. J. Search for Related Content PubMed PubMed Citation Articles by Silverstein, M. J.

Ductal Carcinoma In Situ of the Breast: Controversial Issues

The Breast Center*, Van Nuys, California, USA

Correspondence: Melvin J. Silverstein, M.D., The Breast Center, *A Salick Health Care Subsidiary, 14624 Sherman Way, Sixth Floor, Van Nuys, California 91405, USA. Telephone: 818-787-9911; Fax: 818-787-8853; e-mail: melsilver9{at}aol.com

Ductal carcinoma in situ (DCIS) of the breast is a heterogeneous group of lesions with diverse malignant potential and a range of controversial treatment options. It is the most rapidly growing subgroup in the breast cancer family, with more than 36,000 new cases diagnosed in the United States during 1997. Most new cases are nonpalpable and discovered mammographically. In this overview, a variety of controversial issues are discussed, including: whether or not DCIS should be considered cancer, the fallacy of grouping lesions by their pathologic architecture, an algorithm to aid in the complex treatment-selection process, the profound importance of excision margins, and the outcome following invasive local recurrence, in terms of distant recurrence and mortality. Current approaches to DCIS are based on morphology rather than etiology. In all likelihood, genetic changes precede morphologic evidence of malignant transformation. Medicine must learn how to recognize these genetic changes, exploit them, and, in the future, prevent them.

Key Words. DCIS • Ductal carcinoma in situ • Noninvasive breast cancer • Intraductal breast cancer

This article has been cited by other articles:

				S. J. Katz, P. M. Lantz, N. K. Janz, A. Fagerlin, K. Schwartz, L. Liu, D. Deapen, B. Salem, I. Lakhani, and M. Morrow Patterns and Correlates of Local Therapy for Women With Ductal Carcinoma-In-Situ J. Clin. Oncol., May 1, 2005; 23(13): 3001 - 3007. [Abstract] [Full Text] [PDF]

				V. Shim, M. L. Gauthier, D. Sudilovsky, K. Mantei, K. L. Chew, D. H. Moore, I. Cha, T. D. Tlsty, and L. J. Esserman Cyclooxygenase-2 Expression Is Related to Nuclear Grade in Ductal Carcinoma in Situ and Is Increased in Its Normal Adjacent Epithelium Cancer Res., May 15, 2003; 63(10): 2347 - 2350. [Abstract] [Full Text] [PDF]